Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune system to target and eradicate cancer cells. Cellectis has 17 years of expertise in gene editing based on its flagship TALEN® technology and pioneering electroporation system PulseAgile. This enables us to develop a new generation of immunotherapy product candidates with additional safety and efficacy attributes and equip them to resist mechanisms that inhibit immune system activity.